The US National Eye Institute (NEI) will be sponsoring the first gene therapy trials in X-linked retinoschisis, led by NEI Director Dr. Paul Sieving M.D.,… Read More »First X-linked retinoschisis gene therapy trial launches with support of the US NEI
Research, published in the New England Journal of Medicine (NEJM), has concluded that aflibercept is more effective than bevacizumab and ranibizumab at improving vision for… Read More »NEJM research recommends use of aflibercept (Eylea) as first-line therapy in patients with a VA of 20/50 or worse
Research published in the journal Translational Vision Science & Technology (TVST, 2014, Vol. 3, No. 6,Article 5) reports that a first-in-man study of a “posterior… Read More »Novel micro-pump device for sustained delivery of anti-VEGF treatments completes first-in-man safety study
Researchers based at the Cantonal Hospital of Lucerne, Switzerland have published research findings suggesting a modest superiority of aflibercept (2 mg) and ranibizumab (0.5 mg)… Read More »Swiss study concludes a modest clinical superiority of aflibercept (2 mg) and ranibizumab (0.5 mg) over other anti-VEGF formulations and dosages
Results of a subgroup analysis of Japanese wet AMD patients participating in the VIEW2 intravitreal aflibercept study has shown that the treatment is as well… Read More »Japanese subgroup analysis from VIEW2 study of aflibercept (IVT-AFL) indicate consistent results with larger study population
The number of new drug approvals for 2014 by the European Medicines Agency (EMA), and by the US Food and Drug Administration (FDA), has increased… Read More »EMA and FDA approvals of new drugs increase significantly in 2014
Joint research conducted between the Departments of Ophthalmology at Columbia University, New York and Harvard Medical School, Massachusetts has shown that a novel methodology for… Read More »Quantification of fundus auto-fluorescence (qAF) in recessive Stargardt’s disease (STGD1) patients may contribute to improved outcome measures for clinical trials
The first approved gene therapy in the EU is scheduled to go on sale shortly at a price of €1.1M per treatment. The product, marketed… Read More »First European gene therapy scheduled to go on sale for €1.1M per treatment
SPK-RPE65, a novel gene therapy undergoing development for the treatment of nyctalopia, has received “breakthrough therapy designation” from the FDA. The drug’s sponsor, Spark Therapeutics,… Read More »FDA assigns breakthrough therapy designation to innovative gene therapy approach to nyctalopia (night blindness)
A new Phase II clinical trial based in the US has been commenced to compare three separate doses of intravitreal ALG-1001 (“Luminate”) against bevacizumab or… Read More »Phase II study initiated with novel anti-integrin compound for the treatment of diabetic macular edema (DME)